Development of personalized immunotherapy for urological cancer - generation of genetically engineered neoantigen-specific T cell.

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K20976
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0906:Surgery related to the biological and sensory functions and related fields
• Research Institution: Osaka University
• Principal Investigator: Okuda Yohei 大阪大学, 医学部附属病院, 医員 (10964372)
• Project Period (FY): 2022-08-31 – 2024-03-31
• Keywords: ネオアンチゲン特異的T細胞 / 腎細胞癌

Outline of Final Research Achievements

Neoantigens are tumor-specific antigens consisting of mutant peptides of approximately 8-11 mer, which are antigen-presented on HLA on cancer cells. Neoantigens are highly immunogenic and induce potent cytotoxicity against cancer cells by host T cells. In this study, we used next-generation sequencing technology to predictively identify patient-specific neoantigens from renal tumor samples of six in-house renal cell carcinoma cases and to induce neoantigen-specific T cells to target them.

Free Research Field

泌尿器科

Academic Significance and Societal Importance of the Research Achievements

患者固有のネオアンチゲンの予測同定を行い、それらを標的として特異的に認識するTCRを解析する事、そして、ネオアンチゲン特異的遺伝子改変T細胞を作成し、その腫瘍に対する細胞傷害性評価する事が本研究で確立できれば、将来的に、遺伝子改変ネオアンチゲン特異的T細胞をEx vivoで誘導し、患者個別のOff-the-shelf遺伝子改変ネオアンチゲン特異的T細胞療法を提供する事が実現可能となる。